Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

AIMS: Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) are at very high risk of cardiovascular events. This post‐hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganda, Om P., Plutzky, Jorge, Sanganalmath, Santosh K., Bujas‐Bobanovic, Maja, Koren, Andrew, Mandel, Jonas, Letierce, Alexia, Leiter, Lawrence A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175384/
https://www.ncbi.nlm.nih.gov/pubmed/29802688
http://dx.doi.org/10.1111/dom.13384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175384/
https://www.ncbi.nlm.nih.gov/pubmed/29802688
http://dx.doi.org/10.1111/dom.13384

Ejemplares similares